We have confirmed anti-lymphoma activity of the tumor cell CD47 targeting as shown in xenograft modeling described in this report, although we have yet to demonstrate direct evidence of the role of Teff CD47 targeting in anti-lymphoma activity. This evidence concerns the gene CD47 and neoplasm.